Merck & Co., Inc. (TSX:MRK)
Canada · Delayed Price · Currency is CAD | Market Cap | 444.91B +60.0% |
| Revenue (ttm) | 94.53B +4.6% |
| Net Income | 4.51B -80.7% |
| EPS | 1.81 -80.4% |
| Shares Out | n/a |
| PE Ratio | 98.74 |
| Forward PE | 14.73 |
| Dividend | 0.76 (2.68%) |
| Ex-Dividend Date | Jun 15, 2026 |
| Volume | 400 |
| Open | 28.28 |
| Previous Close | 28.58 |
| Day's Range | 28.28 - 28.38 |
| 52-Week Range | 17.66 - 30.21 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock produ... [Read more]
Financial Performance
In 2025, Merck & Co.'s revenue was $65.01 billion, an increase of 1.31% compared to the previous year's $64.17 billion. Earnings were $18.25 billion, an increase of 6.64%.
Financial numbers in USD Financial StatementsNews
Merck says FDA accepts sBLA for enflonsia
Merck (MRK) announced that the U.S. FDA has accepted a supplemental Biologics License Application for enflonsia to expand its indication to include prevention of respiratory syncytial virus lower resp...
U.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Season
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has accepted a su...
Merck announces Health Canada approval of KEYTRUDA for adults with MIBC
Merck (MRK) announced that KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with enfortumab vedotin, an antibody-drug conjugate, is approved by Health Canada as neoadjuvant treatment and then conti...
Merck price target raised to $116 from $113 at Morgan Stanley
Morgan Stanley analyst Terence Flynn raised the firm’s price target on Merck (MRK) to $116 from $113 and keeps an Equal Weight rating on the shares. Pipeline progress “continues to…
Merck price target raised to $146 from $145 at Guggenheim
Guggenheim analyst Vamil Divan raised the firm’s price target on Merck (MRK) to $146 from $145 and keeps a Buy rating on the shares after Q2 results came in above…
Merck & Co. Earnings Call Transcript: Q2 2026
Q2 revenue rose 5% to $16.6B, led by oncology, animal health, and new launches. Guidance for 2026 was raised, with EPS expected at $2.66–$2.76, including a $2.31/share one-time charge. Major regulatory approvals and pipeline advances de-risk future growth.
Merck & Co. Earnings release: Q2 2026
Merck & Co. released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Merck & Co. Slides: Q2 2026
Merck & Co. has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Merck Cuts Full-Year Profit Forecast as Acquisition Costs Weigh on Bottom Line
Merck slashed its profit outlook for the year due to charges tied to its acquisition of cancer biotech company Terns Pharmaceuticals.
Merck posts better-than-expected second-quarter results on Keytruda strength
Merck reported higher-than-expected second-quarter sales on Tuesday and raised its full-year revenue forecast on the strength of its top-selling cancer treatment Keytruda.
Merck hikes revenue outlook as new drug sales grow, but cuts profit guidance due to deal charges
Merck beat second-quarter estimates and hiked its revenue outlook, as a slate of new products showed strong growth. But the pharmaceutical giant cut its profit guidance due to a charge tied to its ac...
Merck Delivers a Clean Earnings Beat on Oncology Strength. Is It Enough to Impress Wall Street?
The drugmaker posts a narrower-than-expected quarterly loss fueled by growth in its oncology segment.
Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline
RAHWAY, N.J.--(BUSINESS WIRE)--Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results.
Merck & Co. Transcript: Investor update
Significant progress was highlighted in advancing once-weekly and monthly oral HIV regimens, with positive phase III data for ISL/LEN and promising results for ISL/ULO and alimatravir. The portfolio targets both treatment and prevention, aiming for over $5 billion in revenue by the mid-2030s, with long-acting regimens expected to dominate.
Merck & Co. Slides: Investor update
Merck & Co. has posted slides in relation to its latest quarterly earnings report, which was published on August 3, 2026.
Merck, Wellcome partner with global health group to make Ebola vaccine for clinical trials
Hilleman Laboratories, a Singapore-based joint venture between Merck and the global charity Wellcome, is gearing up to manufacture doses of a promising experimental vaccine against the rare Bundibug...
Merck Announces Fourth-Quarter 2026 Dividend
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Announces Fourth-Quarter Dividend.
Merck price target raised to $150 from $140 at Barclays
Barclays analyst Emily Field raised the firm’s price target on Merck (MRK) to $150 from $140 and keeps an Overweight rating on the shares. The firm adjusted targets in the…
Merck announces initial access plans for alimatravir
Merck (MRK) announced early components of a multi-faceted strategy to provide rapid, broad and sustainable access in low- and middle-income countries to alimatravir, an investigational, novel, once-mo...
Merck licenses experimental HIV pill to generic makers in 129 countries
Merck said on Friday it signed seven voluntary licensing agreements with generic drug manufacturers to make and sell lower-cost versions of its experimental once-monthly oral HIV pill in 129 low- an...
Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Voluntary licensing agreements cover 129 countries in regions which account for the substantial majority of new HIV diagnoses globally.
Gilead, Merck weekly HIV pill keeps virus suppressed in late-stage trials
Gilead Sciences and Merck said on Tuesday their experimental once-weekly HIV pill kept the virus suppressed in two late-stage trials, supporting regulatory filings for what could become the first re...
Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy
FOSTER CITY, Calif. & RAHWAY, N.J.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the detailed...
What Comes After Merck's Keytruda? The Race for the Next Standard Cancer Treatment.
Many think the next standard cancer treatment will pair two innovations.